HAG
ALXN

HighPoint Advisor Group’s Alexion Pharmaceuticals ALXN Stock Holding History

HighPoint Advisor Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,941
Closed -$529K – 307
2016
Q4 		$529K Buy
+3,941
New +$482K 0.17% 162

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

HighPoint Advisor Group's ALXN Position: Q1 2017 in Review

HighPoint Advisor Group sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 3,941 shares — an estimated $529K sold.

HighPoint Advisor Group first reported a position in ALXN in Q4 2016 and held it in 1 quarter. The position peaked at $529K in Q4 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • HighPoint Advisor Group reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • HighPoint Advisor Group sold 3,941 Alexion Pharmaceuticals shares in Q1 2017, an estimated $529K.
  • HighPoint Advisor Group first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • HighPoint Advisor Group's Alexion Pharmaceuticals position peaked at $529K in Q4 2016.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on HighPoint Advisor Group's 13F filing for Q1 2017, filed 8 Aug 2017.